title: Amylin gene expression mediated by cAMP/PKA and transcription factors HNF-1 and NFY.
abstract: The regulation of amylin gene expression is not clearly understood. In this study, we used the pancreatic beta cell line, INS-1, to evaluate the regulation of amylin gene expression. When INS-1 cells were cultured in media containing IBMX, the ratio of amylin secretion to insulin secretion increased by 200%. This coincided with an increase in amylin mRNA content. Moreover, there was a three to four-fold increase in amylin promoter activity which was inhibited by the specific protein kinase A (PKA) inhibitor, H89. Electrophoretic mobility shift assays (EMSA) demonstrated that IBMX induced protein-DNA binding to the FLAT and CAAT elements of the amylin promoter. Competitive EMSA experiments revealed that these proteins are likely to be HNF-1 and NFY, respectively. IBMX-induced amylin promoter activity was inhibited by mutations in the FLAT and CAAT elements. These results indicate that amylin is positively regulated by cAMP and PKA through the transcription factors HNF-1 and NFY.
authors: Department of Orthopedic Surgery, University of Southern California, 1200 North State Street, GNH 3900, Los Angeles, CA 90033, USA.
authors: Michael W
authors: MW
authors: Cluck
authors: Leon O
authors: LO
authors: Murphy
authors: Jody
authors: J
authors: Olson
authors: Joseph A
authors: JA
authors: Knezetic
authors: Thomas E
authors: TE
authors: Adrian
mesh_terms: D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D000682:Amyloid / Q000235:genetics* / Q000378:metabolism; D000818:Animals; D023081:CCAAT-Binding Factor / Q000378:metabolism*; D002460:Cell Line; D000242:Cyclic AMP / Q000378:metabolism*; D017868:Cyclic AMP-Dependent Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D004268:DNA-Binding Proteins / Q000378:metabolism*; D005786:Gene Expression Regulation; D051537:Hepatocyte Nuclear Factor 1; D051538:Hepatocyte Nuclear Factor 1-alpha; D007328:Insulin / Q000235:genetics / Q000378:metabolism; D058228:Islet Amyloid Polypeptide; D007515:Islets of Langerhans / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D007546:Isoquinolines / Q000494:pharmacology; D016297:Mutagenesis, Site-Directed; D009687:Nuclear Proteins / Q000235:genetics / Q000378:metabolism*; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D011401:Promoter Regions, Genetic; D011485:Protein Binding; D051381:Rats; D013449:Sulfonamides; D014157:Transcription Factors / Q000378:metabolism*
chemical_list: D000682:Amyloid; D023081:CCAAT-Binding Factor; D004268:DNA-Binding Proteins; D051538:Hepatocyte Nuclear Factor 1-alpha; C496489:Hnf1a protein, rat; D007328:Insulin; D058228:Islet Amyloid Polypeptide; D007546:Isoquinolines; D009687:Nuclear Proteins; D010726:Phosphodiesterase Inhibitors; D013449:Sulfonamides; D014157:Transcription Factors; C402244:nuclear factor Y; D051537:Hepatocyte Nuclear Factor 1; D000242:Cyclic AMP; D017868:Cyclic AMP-Dependent Protein Kinases; C063509:N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide; D015056:1-Methyl-3-isobutylxanthine